Benzinga | Jul 13, 2021 10:29AM EDT

Canaccord Genuity Maintains Buy on Bicycle Therapeutics, Raises Price Target to $36

Canaccord Genuity analyst Arlinda Lee maintains Bicycle Therapeutics (NASDAQ:BCYC) with a Buy and raises the price target from $30 to $36.